Hip Replacement Statistics in US 2026 | Success Rates, Costs & Key Facts

Hip Replacement in the US 2026: Volume, Demand & What the Data Shows

Hip replacement surgery — formally known as total hip arthroplasty (THA) — has become one of the most performed elective surgical procedures in the United States, and in 2026, both its volume and its profile are changing faster than at any point in its history. Approximately 330,000 to 469,000 hip replacements are performed in the US every year depending on the data source, with the American Joint Replacement Registry (AJRR) — the world’s largest arthroplasty registry by annual procedure count — having now captured more than 4 million hip and knee arthroplasties in its database since 2012. Projections from the Journal of Rheumatology estimate that the US will see 850,000 total hip replacements per year by 2030, rising to 1.4 million by 2040 — figures that underscore the degree to which population ageing and rising obesity rates are driving demand for joint reconstruction surgery at a pace the healthcare system is only beginning to plan around.

The 2026 landscape for hip replacement is defined by three structural shifts happening simultaneously. First, the outpatient revolution: procedures that once required a three-to-five-day hospital stay are now routinely performed as same-day surgeries, with the American Academy of Orthopaedic Surgeons (AAOS) projecting that 51% of all joint replacements will be performed on an outpatient basis by 2026. Second, the cost transformation: uninsured patients face charges of $32,000 to $65,000 or more, while Medicare patients in outpatient ambulatory surgical centres pay an average out-of-pocket cost of roughly $2,154 — a disparity that reflects the fragmented pricing architecture of American healthcare. Third, the younger patient shift: THA in patients aged 55 and under is projected to increase fivefold by 2030, creating a population of recipients who need implants to last 30 or more years and who face substantially higher lifetime revision rates than older patients. All data in this article reflects verified sources as of May 23, 2026.

Key Fast Facts: US Hip Replacement Statistics 2026

US HIP REPLACEMENT — FAST FACTS SNAPSHOT (2026)
════════════════════════════════════════════════════════════════
  Annual US Hip Replacements (approx.)     ████████████████████  330,000–469,000/year
  AJRR Total Database (as of 2024 report)  ████████████████████  4+ million procedures
  AJRR Member Institutions                 ████████████████████  1,447 across all 50 states
  Projected US THAs by 2030                ████████████████████  850,000/year
  Projected US THAs by 2040                ████████████████████  1.4 million/year
  10-Year Implant Survival Rate            ████████████████████  93.6–95.6%
  20-Year Implant Survival Rate            ████████████████████  85.0%
  Patient Satisfaction Rate                ████████████████████  ~90–95%
  Average Cost — Uninsured (2026)          ████████████████████  $32,000–$65,000
  Average Cost — With Medicare (outpatient) ██                   ~$2,154 out-of-pocket
  Outpatient Share of Procedures (2026)    ████████████████████  ~40–51%
  US Incidence Increase (2000–2016)        ████████████████████  +187%
════════════════════════════════════════════════════════════════

Source: AJRR 2024 Annual Report (AAOS), National Hospital Discharge Survey, CDC, Journal of Rheumatology, European Arthroplasty Register, NHANES, AAOS, ScienceDirect — 2019–2026

The 187% increase in hip replacement incidence between 2000 and 2016 is not simply a population growth story — the US population did not increase by anything close to 187% in that period. It reflects a genuine shift in clinical practice: lower surgical thresholds, earlier intervention for moderate arthritis, greater patient awareness and expectation, an ageing boomer cohort entering the high-risk age bracket, and rising obesity rates that accelerate joint degeneration. The AJRR’s 4-million-procedure milestone is significant not just as a number but as a data infrastructure achievement: the registry enables longitudinal outcome tracking at a scale that was impossible a decade ago, informing implant selection, surgical technique refinement, and early detection of device failures in ways that directly improve patient outcomes.

The outpatient revolution deserves particular attention. The shift of hip replacement from a multi-day inpatient admission to a same-day surgical centre procedure — now covering 40–51% of candidates — is one of the most consequential changes in joint replacement surgery in decades. It has been enabled by enhanced recovery after surgery (ERAS) protocols, improved anaesthetic techniques, better pain management, and more selective patient screening. For healthcare costs, the shift is significant: outpatient hip replacement typically costs $12,000 to $20,000 less than the inpatient equivalent purely through the elimination of overnight facility fees, reducing both insurer and patient financial exposure substantially.

Hip Replacement Success Rates 2026 | Implant Survival, Revision & Complications

HIP REPLACEMENT IMPLANT SURVIVAL RATES — BY TIME HORIZON
════════════════════════════════════════════════════════════════
  5-Year Survival (general population)        ████████████████████  ~98%
  10-Year Survival (Lancet, 63,158 patients)  ████████████████████  95.6%
  10-Year Survival (NZJR registry)            ████████████████████  93.6%
  20-Year Survival (Lancet)                   ████████████████████  85.0%
  10-Year Survival (age 90–95 at surgery)     ████████████████████  97.5%
  10-Year Survival (age 46–50 at surgery)     █████████████████     93.0% (lower end)
  20-Year Survival (age ≤55 at surgery)       ████████████          60.4–77.7%
  Lifetime Revision Risk (age 46–50)          ▼▼▼▼▼▼▼▼             27.6%
  Lifetime Revision Risk (age 90–95)          ▼                     1.1%
  Lifetime Revision Risk (age 70+)            ▼▼                    ~5%
════════════════════════════════════════════════════════════════
  Patient satisfaction: ~90–95% report significant pain relief

Source: The Lancet (63,158 THA patients), New Zealand Joint Registry (NZJR), Bone & Joint Journal, ScienceDirect (35-study scoping review), Harvard/HMS volume-outcome study, Gitnux 2026 — 2017–2026

The 95.6% ten-year implant survival rate from the Lancet’s landmark population-based cohort study — tracking more than 63,000 THA patients — is the most cited benchmark in hip replacement outcomes research, and it represents genuinely impressive engineering. The artificial joint that replaced a degenerated hip not only eliminates pain in the vast majority of cases but continues functioning without requiring surgical revision in more than nineteen out of twenty patients through the first decade after surgery. For older patients — those in their 70s, 80s, and 90s — the outcomes are even better, partly because these patients are less physically active (placing less wear on the implant) and partly because at 97.5% ten-year survival for the 90–95 age group, most patients will die with their original implant intact.

The younger patient picture is substantially more complex. For patients in their late 40s and early 50s — a rapidly growing surgical cohort as thresholds for intervention have lowered — the 20-year survival rate drops to 60.4–77.7%, and the lifetime revision risk reaches 27.6% for those aged 46–50. Men in their early 50s face the highest lifetime revision risk of any group, at up to 35%. The reasons are straightforward: younger, more active patients place significantly more mechanical stress on their implants through a longer post-operative lifespan; the wear and micromotion that occur during decades of walking, running, climbing stairs, and carrying weight eventually lead to aseptic loosening — the most common cause of revision surgery. The surgeon volume data from Harvard adds another critical dimension: patients treated by surgeons performing more than 50 THAs per year in Medicare beneficiaries had a dislocation rate of 1.5%, compared to 4.2% for those treated by surgeons performing five or fewer per year — a nearly threefold difference in complication risk based on a single measurable institutional factor.

Hip Replacement Cost in the US 2026 | By Insurance Type, Setting & State

HIP REPLACEMENT COST BREAKDOWN — 2026 (BY INSURANCE STATUS)
════════════════════════════════════════════════════════════════
  Uninsured / Cash-Pay (inpatient hospital)   $32,000 – $65,000
  Uninsured (hospital charge, some centres)   Up to $50,000+ gross charge
  Private Insurance (patient out-of-pocket)   $3,000 – $9,000 (deductible + coinsurance)
  Private Insurance (pays 150% of Medicare)   Reimburses ~$20,000–$30,000 to hospital
  Medicare (outpatient ASC, patient share)     ~$2,154 out-of-pocket
  Medicare (hospital outpatient, patient)      ~$1,884–$1,927 out-of-pocket
  Medicare (inpatient, Part A deductible)      $1,736 deductible (2026)
  Bundled cash price (Surgery Center model)   $15,000–$20,000 inclusive
  Outpatient vs. Inpatient saving              $12,000–$20,000 less
  Robotic-assisted surgery premium             +$7,000 above standard cost
════════════════════════════════════════════════════════════════
  Cheapest state 2026: Mississippi ($28,320)
  Most expensive: Urban Northeast and California (up to $95,000)

Source: SurgeryCostGuide 2026, FindADoc 2026, GoodRx, PennyCheck 2026, Medicare.org, Solace Health, Wellcare, Aetna Medicare, Humana Medicare — 2025–2026

The cost data for hip replacement in 2026 illustrates one of the most extreme price disparities in American healthcare. A Medicare patient with supplemental (Medigap) coverage can have a total hip arthroplasty for an out-of-pocket cost approaching zero beyond their monthly premiums — while an uninsured 48-year-old presenting at a hospital in New York or San Francisco for the same procedure may face a gross charge of $65,000 to $95,000. The implant that is placed inside both patients’ bodies is often identical. The $15,000–$20,000 bundled cash price available at transparency-focused surgical centres in some states — covering surgeon, facility, implant, and follow-up care — suggests that the procedure’s actual cost of delivery is substantially lower than what most institutional settings charge, and that the prevailing pricing structure reflects negotiating power and market dynamics as much as actual resource consumption.

The robotic-assisted surgery premium of $7,000 is a figure worth scrutinising. Robotic systems — primarily the Mako SmartRobotics platform (Stryker) — have been widely marketed in hip replacement as improving component positioning accuracy and reducing soft tissue trauma. The evidence on whether those advantages translate into meaningfully improved long-term implant survival rates at the population level remains mixed in the peer-reviewed literature, but patient demand and hospital marketing investment in robotic systems is accelerating. For most patients choosing between standard and robotic-assisted THA, the $7,000 premium is an out-of-pocket consideration only for those in high-deductible plans or those paying cash; for standard Medicare beneficiaries, the choice typically does not change their out-of-pocket exposure.

Hip Replacement Demographics 2026 | Age, Gender, Race & Risk Factors

HIP REPLACEMENT DEMOGRAPHICS — US 2026
════════════════════════════════════════════════════════════════
  Peak Age Group for Primary THA           ████████████████████  65–80 years
  Fastest Growing Age Cohort               ████████████████████  Under 55 (projected 5x by 2030)
  THA in adults 45+ (US prevalence)        ████                  1.28% of 45+ population
  Primary indication                       ████████████████████  Osteoarthritis (dominant)
  Hip fracture leading to replacement      ████                  20–30% (in over-65s)
  Men in early 50s — lifetime revision risk ████████████████████ Up to 35%
  Women in early 50s — lifetime revision    ████████████         ~15–20% lower than men
  Older Black Americans — OA disparity     ████████████████████  Less likely to receive THA
  Antibiotic prophylaxis rate              ████████████████████  98%
  Tranexamic acid (TXA) use                ████████████████████  ~95%
════════════════════════════════════════════════════════════════
  Same-day discharge in ~10% of Medicare patients
  Surgeon volume >100/yr: lower mortality vs ≤10/yr (0.7% vs 1.3%)

Source: AJRR 2024 Annual Report, The Lancet, Harvard/HMS volume-outcome study, NHANES, AAOS, ScienceDirect — 2019–2026

The demographic data reveals a hip replacement system that is shifting rapidly younger even as it continues to serve its core older population. The projected fivefold increase in THA among under-55 patients by 2030 is perhaps the single most consequential trend for long-term healthcare planning: these patients need their implants to last 30, 35, or even 40 years, a duration for which current implant materials — while far improved over those from the 1970s and 1980s — have not yet accumulated adequate clinical follow-up data. The 20-year survival rate of 60.4–77.7% for patients aged 55 and under is the best currently available evidence for this group, and the wide range reflects genuine uncertainty about outcomes at the boundaries of available follow-up windows.

The racial disparity in THA access is documented but underquantified in 2026 data. Black Americans experience osteoarthritis at broadly similar rates to white Americans but are consistently less likely to receive hip replacement surgery, less likely to be referred by primary care physicians, less likely to accept referral when offered, and more likely to face financial and access barriers that make elective surgery difficult to arrange. The AJRR’s expansion of patient-reported outcomes (PROMs) collection — now submitted by 44% of member sites, a 27% increase year-over-year — represents the data infrastructure being built to eventually quantify these disparities at the individual patient level and track whether interventions to reduce them are working.

Hip Replacement Recovery & Procedure Facts 2026 | Techniques, Implants & Outcomes

HIP REPLACEMENT — PROCEDURE & RECOVERY FACTS (2026)
════════════════════════════════════════════════════════════════
  Typical Hospital Stay (standard inpatient)    1–3 days
  Same-Day Discharge Rate (Medicare patients)   ~10%
  Time to Walk Unaided (avg)                   4–6 weeks
  Full Recovery Timeline                        3–6 months
  Return to Light Activity                      6–12 weeks
  Return to Driving                             4–6 weeks (depending on operated side)
  Physical Therapy Duration                     6–12 weeks post-op
  Average Incision Length                       ~12 cm (standard approach)
  Anterior (muscle-sparing) approach use        Growing — now majority at many centres
  Lateral approach (declining)                  ~15% of procedures
  Uncemented press-fit cups used                ~92% of procedures
  Head sizes >36mm                              Used in ~30% of primaries
  ERAS protocols in use                         ~60% of US hospitals
  Average blood loss (with TXA)                 ~200ml
  Tranexamic acid (TXA) administration          ~95% of procedures
  DVT prophylaxis (enoxaparin)                  ~70% of procedures
════════════════════════════════════════════════════════════════

Source: Gitnux 2026, AJRR 2024, Harvard/HMS volume-outcome study, GoodRx, SurgeryCostGuide 2026, AAOS — 2024–2026

The ERAS (Enhanced Recovery After Surgery) protocol adoption — now in use at approximately 60% of US hospitals — is the single clinical innovation most responsible for the shift to outpatient hip replacement. ERAS protocols bundle multiple evidence-based interventions: multimodal anaesthesia that reduces opioid requirements, pre-operative optimisation of nutrition and fitness, intraoperative fluid management, early mobilisation on the day of surgery, and structured post-operative pain management that enables discharge within hours rather than days. By cutting average length of stay by approximately one day — saving an estimated $2,500 per case in facility fees — ERAS protocols have simultaneously improved patient experience and reduced system costs, one of the rare situations in healthcare where the evidence supports doing less (hospitalisation) to achieve better results.

The near-universal adoption of tranexamic acid (TXA) — now used in approximately 95% of procedures — represents another decade-defining clinical shift. TXA, an antifibrinolytic drug that reduces surgical bleeding by preventing the breakdown of blood clots, has reduced average intraoperative blood loss to approximately 200ml in THA, dramatically cutting the rate of blood transfusion (which carries its own risks and costs) and shortening recovery. Combined with 98% antibiotic prophylaxis administration — essentially universal pre-operative antibiotic coverage — the surgical infection and haemorrhagic complication rates of 2026 hip replacement are substantially lower than those of a decade ago, even as the volume of procedures and the complexity of the patient population (younger, heavier, more medically complex) has increased.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE